Results 41 to 50 of about 5,674 (178)

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture

Frontiers in Microbiology, 2022
We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection.
Carlos García-Crespo, Carlos García-Crespo, Lucía Vázquez-Sirvent, Lucía Vázquez-Sirvent, Pilar Somovilla, Pilar Somovilla, María Eugenia Soria, María Eugenia Soria, María Eugenia Soria, Isabel Gallego, Isabel Gallego, Ana Isabel de Ávila, Ana Isabel de Ávila, Brenda Martínez-González, Brenda Martínez-González, Antoni Durán-Pastor, Esteban Domingo, Esteban Domingo, Celia Perales, Celia Perales, Celia Perales, Celia Perales   +21 more
doaj   +1 more source

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy

Archives of Pharmaceutical Sciences Ain Shams University, 2021
Hepatitis C virus (HCV) was first identified in 1989. The situation in Egypt is really dire. The prevalence of HCV genotype 4 (GT-4) is 14.7%. About 10% of the middle-aged population (ages 15 to 59) is infected with HCV.
Heba Elbadawy, Sara Wahdan, Ebtehal El-Demerdash   +2 more
doaj   +1 more source

Daclatasvir sensitivity profile and validation.

, 2014
(A) A heat map shows the fitness landscape shift under Daclatasvir treatment (20 pM), which is calculated as the ratio of relative fitness scores (Wdrug/Wcontrol). The mutants that are lethal without drug are shown in grey. The secondary structure of DIA
Virginia Chu (549943), Shawna Truong (549944), James O. Lloyd-Smith (24136), Ren Sun (82856), Laith Q. Al-Mawsawi (307260), Nicholas C. Wu (549942), Claude Loverdo (434144), C. Anders Olson (549941), Sheng-Yao Su (368663), Roland Remenyi (270101), Chung-Yen Lin (10205), Zugen Chen (76247), Ruian Ke (102243), Ting-Ting Wu (1693231), Hangfei Qi (549940), Weidong Zhong (120728), Yushen Du (549945), Shu-Hua Chen (549946)   +17 more
core   +1 more source

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 [PDF]

, 2021
Background: Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality.
Souza, TML, Rajoli, RKR, Ju, J, Garzia, A, Bou-Habib, DC, Da Silva, ADPD, Ferreira, MA, Xie, W, De Freitas, CS, Bastos, MME, Pedrosa, CSG, Temerozo, JR, Boechat, N, Bozza, PT, Vitória, G, Guimarães, MZ, Bozza, FA, Wang, X, Dias, SDSG, Owen, A, Goto-Silva, L, Souza, LRQ, Chien, M, Soares, VC, Patel, D, Tao, C, Rehen, SK, Hoelz, LVB, Jockusch, S, Tuschl, T, Russo, JJ, Branco, FSC, Da Silva, CDS, Fernandes, TVA, Sacramento, CQ, Fintelman-Rodrigues, N, Pão, CRR, Ferreira, AC, Mattos, M, Saraiva, FB   +39 more
core   +1 more source

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon, Jumpei Kondo, Yuki Tahata, Hayato Hikita, Maki Iwaisako, Muya Matsumoto, Asuka Ogata, Shinji Takamatsu, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Yuichi Yoshida, Masanori Nakahara, Kazuho Imanaka, Mitsuru Sakakibara, Takayuki Yakushijin, Tetsuo Takehara, Takahiro Kodama, Eiji Miyoshi   +19 more
wiley   +1 more source

Efficacy of Sofosbuvir and Daclatasvir in Achieving the End Treatment Response and Sustained Viral Response in Patients infected with Hepatitis C Virus Genotype 3

Pakistan Armed Forces Medical Journal, 2022
Objective: To ascertain the efficacy of sofosbuvir combined with daclatasvir against hepatitis C genotype 3 infection. Study Design: Prospective longitudinal study.
Zabih Ullah, Sultan Zeb Khan, Hassam Lodhi, Hafizullah Khan, Rania Hidayat, Moiz Ahmed   +5 more
doaj   +1 more source

Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2)

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims Ensuring access to direct‐acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9‐year period spanning before and after August 2017, when the country implemented universal DAA access.
Fabienne Marcellin, Clémence Ramier, Cécile Brouard, Vincent Di Beo, Yoann Allier, Abbas Mourad, Morgane Bureau‐Stoltmann, Philippe Sogni, Sylvie Deuffic‐Burban, Patrizia Carrieri, Benjamin Rolland, Marc Bourliere, Camelia Protopopescu   +12 more
wiley   +1 more source

Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of Viral Genome to Assembly Sites.

, 2016
International audienceDaclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranous web shaping, and assembly of new virions, likely via ...
Boson, Bertrand, Chamot, Christophe, Denolly, Solène, Dreux, Marlène, Turlure, Fanny, François-Loïc, Cosset, Cosset, François-Loïc   +6 more
core   +1 more source

METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM [PDF]

, 2016
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.
A, Praveen Kumar, Chakravarthy V, Ashok, Bbv, Sailaja   +2 more
core   +3 more sources